Ukko Raises $40M Series B Financing

January 27, 2021Client News

Gunderson Dettmer represented client Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, in its $40 million Series B financing led by Leaps by Bayer. The new funding will be used to advance its efforts in ending food allergies for good.

In the announcement of the transaction, CEO and co-founder of Ukko Anat Binur said, “The core of our approach is our AI-driven platform, which allows us to go to a protein at a component level and precisely engineer it in a way that keeps the good and gets rid of the bad.”

The Gunderson deal team was led by Ilan Lovinsky and included Jonathan Spencer and Mike Deitch.